Senti Biosciences Holdings, Inc. (SNTI) · Oct 26, 2026 · Disposition
Core pipeline divested — SENTI-202 and substantially all existing business transferred; $3.1M pro forma cash remains
Senti Biosciences’ divestiture closes: SENTI-202 moves out, while Rett and TIL programs remain with only $3.1M pro forma cash.
Senti is moving from a broader cell-therapy company into a much smaller public biotech focused on an early Rett Syndrome program and a Regulator Dial-enabled TIL platform; the transaction was announced in July, so the strategic direction was already known.
The divestiture is now the company’s defining event. Senti has transferred Midco and Opco—and therefore substantially all of its existing business and pipeline, including SENTI-202—to the buyer, while retaining the Rett Syndrome and TIL programs.
The retained business has assets, but not a meaningful operating platform yet. The assignment gives Senti the patents, know-how and agreements needed for the Rett and TIL fields, but the contract explicitly excludes SENTI-202; the company must also rely on Opco for transitional accounting, legal, systems and R&D support. 〔0〕
| Pro forma metric | Six months ended June 30, 2026 | Year ended December 31, 2025 | Filing location |
|---|---|---|---|
| Cash and cash equivalents | $3.1M | — | Pro Forma Balance Sheet |
| Net loss | $(3.9)M | $(15.5)M | Pro Forma Statements of Operations |
| Net loss per share | $(0.05) | $(0.20) | Pro Forma Statements of Operations |
| Weighted-average shares | 85.2M | 76.6M | Pro Forma Statements of Operations |
| Parent capital contribution | $2.5M | — | Note 2B |
| Notes exchanged for shares | $16.0M | — | Notes 2H and 2J |
| Estimated loss on disposal | $6.7M | — | Merger Consideration and Estimated Loss on Disposal |
The financing buys time, not sustainability. Parent contributed $2.5 million, but the pro forma balance sheet leaves only $3.1 million of cash and $673,000 of liabilities. Management says operations may not be maintainable as early as the fourth quarter of 2026 and that additional funding is required. 〔1〕
The capital structure becomes much more dilutive. The forced exchange of $16.0 million of notes is expected to issue 46.8 million shares, while the parent contribution adds another 7.3 million shares; the pro forma share count rises from 31.1 million historical shares for the first half of 2026 to 85.2 million. The reverse split authorization may help with listing mechanics, but it does not solve the funding gap.
The CVR is upside for existing holders, not operating capital for Senti. Holders may receive up to $60 million if SENTI-202 reaches specified FDA and sales milestones, but those payments come from Midco directly and do not fund the remaining public company. 〔2〕
Bottom line: The closing completes a known strategic separation, leaving Senti with the Rett and TIL concepts but removing its lead clinical asset and most operating infrastructure. It is a cleaner story, yet one that remains financially fragile and dependent on near-term fundraising.
Additional financing to fund continued operations
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!